X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

Monoclonal Anti-Assembly Protein 180 antibody produced in mouse

RRID:AB_258203

Antibody ID

AB_258203

Target Antigen

Assembly Protein 180 antibody produced in mouse human, bovine, rat, bovine, human, rat

Proper Citation

(Sigma-Aldrich Cat# A4825, RRID:AB_258203)

Clonality

monoclonal antibody

Comments

Vendor recommendations: IgG2b Western Blot; Immunoprecipitation; Immunocytochemistry; immunoblotting: 1:10,000

Host Organism

mouse

Vendor

Sigma-Aldrich

Cat Num

A4825

Publications that use this research resource

Parkinson Sac Domain Mutation in Synaptojanin 1 Impairs Clathrin Uncoating at Synapses and Triggers Dystrophic Changes in Dopaminergic Axons.

  • Cao M
  • Neuron
  • 2017 Feb 22

Literature context:


Abstract:

Synaptojanin 1 (SJ1) is a major presynaptic phosphatase that couples synaptic vesicle endocytosis to the dephosphorylation of PI(4,5)P2, a reaction needed for the shedding of endocytic factors from their membranes. While the role of SJ1's 5-phosphatase module in this process is well recognized, the contribution of its Sac phosphatase domain, whose preferred substrate is PI4P, remains unclear. Recently a homozygous mutation in its Sac domain was identified in early-onset parkinsonism patients. We show that mice carrying this mutation developed neurological manifestations similar to those of human patients. Synapses of these mice displayed endocytic defects and a striking accumulation of clathrin-coated intermediates, strongly implicating Sac domain's activity in endocytic protein dynamics. Mutant brains had elevated auxilin (PARK19) and parkin (PARK2) levels. Moreover, dystrophic axonal terminal changes were selectively observed in dopaminergic axons in the dorsal striatum. These results strengthen evidence for a link between synaptic endocytic dysfunction and Parkinson's disease.

Funding information:
  • NCATS NIH HHS - UL1 TR001863()
  • NIDA NIH HHS - P30 DA018343()
  • NIGMS NIH HHS - P41 GM103412()
  • NINDS NIH HHS - R01 NS036251()
  • NINDS NIH HHS - R01 NS036942()
  • NINDS NIH HHS - R37 NS036251()
  • NINDS NIH HHS - R37 NS036942()

Clathrin assembly proteins AP180 and CALM in the embryonic rat brain.

  • Schwartz CM
  • J. Comp. Neurol.
  • 2010 Sep 15

Literature context:


Abstract:

Clathrin-coated vesicles are known to play diverse and pivotal roles in cells. The proper formation of clathrin-coated vesicles is dependent on, and highly regulated by, a large number of clathrin assembly proteins. These assembly proteins likely determine the functional specificity of clathrin-coated vesicles, and together they control a multitude of intracellular trafficking pathways, including those involved in embryonic development. In this study, we focus on two closely related clathrin assembly proteins, AP180 and CALM (clathrin assembly lymphoid myeloid leukemia protein), in the developing embryonic rat brain. We find that AP180 begins to be expressed at embryonic day 14 (E14), but only in postmitotic cells that have acquired a neuronal fate. CALM, on the other hand, is expressed as early as E12, by both neural stem cells and postmitotic neurons. In vitro loss-of-function studies using RNA interference (RNAi) indicate that AP180 and CALM are dispensable for some aspects of embryonic neurogenesis but are required for the growth of postmitotic neurons. These results identify the developmental stage of AP180 and CALM expression and suggest that each protein has distinct functions in neural development.

Funding information:
  • NHGRI NIH HHS - P41HG004118(United States)